

## Chapter 10: Pertussis

Amanda Faulkner, MPH; Tami Skoff, MS; Stacey Martin, MSc; Pam Cassiday, MS; Maria Lucia Tondella, PhD, Jennifer Liang, DVM, MPVM; O. Grace Ejigiri, MPH

### I. Disease Description

Pertussis, a cough illness commonly known as whooping cough, is caused by the bacterium *Bordetella pertussis*. The illness is characterized by a prolonged paroxysmal cough often accompanied by an inspiratory whoop. Disease presentation varies with age and history of previous exposure or vaccination. Young infants can present to a clinic or hospital with apnea and no other disease symptoms. Adults and adolescents with some immunity can exhibit only mild symptoms or have the typical prolonged paroxysmal cough. In all persons, cough can continue for months.

Severe disease is infrequent in healthy, vaccinated persons. Infants, particularly those who have not received the primary vaccination series against pertussis, are at risk for complications and mortality. Pneumonia is the most common complication in all age groups. Seizures and encephalopathy are rare and generally only reported in young infants. Death is rare and most likely to occur in young, unvaccinated infants, although fatalities are occasionally reported among older children and adults with serious underlying health conditions.<sup>1</sup>

In addition to *B. pertussis*, three other *Bordetella* species can cause disease in humans: *B. parapertussis*, *B. holmesii*, and *B. bronchiseptica*. *B. parapertussis* causes a pertussis-like illness that is generally milder than pertussis because the bacteria do not produce pertussis toxin. Co-infection of *B. pertussis* and *B. parapertussis* is not unusual. Disease attributable to *Bordetella* species other than *B. pertussis* is not reportable to CDC.

### II. Background

In the pre-vaccine era, pertussis was a common childhood disease and a major cause of child and infant mortality in the United States. Routine childhood vaccination led to a reduction in disease incidence from an average of 150 reported cases per 100,000 persons between 1922 and 1940, to 0.5 per 100,000 in 1976.<sup>2</sup> The incidence of reported pertussis began increasing in the 1980s. In 2009, the incidence of reported pertussis was 5.54 per 100,000 persons (CDC, unpublished data). While the reasons for this increase are not fully understood, multiple factors have likely contributed to the increase including waning immunity from childhood pertussis vaccines, increased recognition of the disease, and better diagnostic testing and increased reporting. The incidence of pertussis remains highest among young infants.<sup>3,4</sup> In 2009, most (12 of 14) pertussis-related deaths reported to CDC were among infants aged younger than 6 months, who were too young to have received three doses of DTaP vaccine (CDC, unpublished data). As of 2009, the second highest incidence of pertussis is observed among school-aged children and adolescents, and the proportion of cases in this age group appears to be increasing.

### III. Importance of Rapid Case Identification

Early diagnosis and treatment might limit disease spread. When pertussis is strongly suspected, attempts to identify and provide prophylaxis to close contacts should proceed without waiting for laboratory confirmation. When suspicion of pertussis is low, the investigation can be delayed until there is laboratory confirmation of the diagnosis. However, prophylaxis of infants and their household contacts should not be delayed because pertussis can be severe and life-threatening to young infants.

### IV. Importance of Surveillance

Surveillance data collected through case investigations are used to assess burden of disease and monitor changes in epidemiology over time. Surveillance data are also used to guide policy and development of control strategies. CDC uses surveillance data to monitor national

trends in disease and identify populations at risk. Local and state health departments use surveillance data to identify clusters of related cases that might indicate an outbreak.

Surveillance data have also been used to guide vaccination policy development. Data collected through an enhanced surveillance program suggested that infants often acquire pertussis from close contacts and supported recommendations for vaccination of postpartum mothers and adult and adolescent contacts of infants.<sup>5-7</sup>

Laboratory surveillance to monitor changes in the *B. pertussis* organism is also important. See Section VII, “Laboratory Testing” for more details.

## V. Disease Reduction Goals

A disease reduction goal of 2,500 indigenous pertussis cases per year in children younger than 1 year of age was proposed as a part of the Healthy People 2020 project.<sup>8</sup> In 2009, 3,206 cases were reported in this group (CDC, unpublished data).

## VI. Case Definitions

The following case definition for pertussis was approved by the Council of State and Territorial Epidemiologists (CSTE) in June 1997.<sup>9</sup>

### *Clinical case definition*

A cough illness lasting at least 2 weeks with one of the following: paroxysms of coughing, inspiratory “whoop,” or posttussive vomiting; and without other apparent cause (as reported by a healthcare professional).

### *Laboratory criteria for diagnosis*

- Isolation of *B. pertussis* from a clinical specimen
- Positive polymerase chain reaction (PCR) assay for *B. pertussis* DNA

### *Case classification*

**Probable:** Meets the clinical case definition, is not laboratory confirmed, and is not epidemiologically linked to a laboratory-confirmed case.

### **Confirmed:**

- A case of acute cough illness of any duration with a positive culture for *B. pertussis*; *OR*
- A case that meets the clinical case definition and is confirmed by PCR; *OR*
- A case that meets the clinical definition and is epidemiologically linked directly to a case confirmed by either culture or PCR

**Comment:** The clinical case definition was designed to increase sensitivity for detecting pertussis cases when confirmatory laboratory testing was not done or was negative. Laboratory tests can be negative even when the patient has pertussis. The clinical case definition is appropriate for endemic or sporadic cases. In outbreak settings, including household exposures, a clinical case can be defined as an acute cough illness lasting 2 weeks or longer without other symptoms. A case definition of cough illness lasting 14 days or longer has demonstrated 84% sensitivity and 63% specificity for detecting culture-positive pertussis in outbreak settings.<sup>10</sup> It is important to note that the outbreak case definition should be used for the epidemiologic investigation and not for reporting purposes.

Collection of epidemiologic and clinical data is essential for reporting cases that meet the clinical case definition. Investigators should make every attempt to collect information on paroxysms of cough, whoop, posttussive vomiting, and duration of cough as these variables are required to determine whether an individual meets the clinical case definition for pertussis. When feasible, case investigations initiated shortly after cough onset should include follow-up calls to collect information on cough duration. Follow-up should be done regardless of confirmatory test results so that cases meeting the clinical case definition can be reported. Both probable and confirmed pertussis cases should be reported to the National Notifiable Diseases

Surveillance System (NNDSS) by the state health department via the National Electronic Telecommunications System for Surveillance (NETSS) or National Electronic Disease Surveillance System (NEDSS).

Laboratory confirmation of pertussis is important because other pathogens can cause symptoms similar to pertussis. Culture of *B. pertussis* is the most specific diagnostic test; all patients with cough and a positive *B. pertussis* culture should be reported as confirmed, even those with cough lasting less than 14 days. PCR is less specific than culture; cases confirmed with only a positive PCR must meet the clinical case definition to be reported as confirmed. To confirm a case by epidemiologic linkage, the case must be directly linked (i.e., a first-generation contact) to a laboratory-confirmed case by either culture or PCR.<sup>9</sup>

## VII. Laboratory Testing

Determining who has pertussis and who does not is often difficult. Whenever possible, a nasopharyngeal swab or aspirate should be obtained from all persons with suspected cases. A properly obtained nasopharyngeal swab or aspirate is essential for optimal results. Health department personnel who are asked to obtain these specimens should receive training and supervision from persons experienced in collection of nasopharyngeal specimens. CDC has developed two short training videos for collection of nasopharyngeal aspirate and swab specimens, which can be accessed on the CDC pertussis website: <http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html>.

### Culture

Isolation of *B. pertussis* by bacterial culture is the standard pertussis diagnostic laboratory test. A positive culture for *B. pertussis* confirms the diagnosis of pertussis. Culture of the organism is also necessary for antimicrobial susceptibility testing and molecular typing.

Although bacterial culture is specific for diagnosis, it is relatively insensitive. Fastidious growth requirements make *B. pertussis* difficult to isolate. Isolation of the organism using direct plating is most successful during the catarrhal stage (i.e., first 1–2 weeks of cough). Success in isolating the organism declines if the patient has received prior antibiotic therapy effective against *B. pertussis*, if specimen collection has been delayed beyond the first 2 weeks of illness, and if the patient has been vaccinated.

All persons with suspected cases of pertussis should have a nasopharyngeal aspirate or swab obtained from the posterior nasopharynx for culture. For *B. pertussis*, nasopharyngeal aspirates will yield similar or higher rates of recovery than nasopharyngeal swabs,<sup>11–14</sup> throat and anterior nasal swabs yield unacceptably low rates of recovery.<sup>15</sup> Therefore, specimens should be obtained from the posterior nasopharynx (Figure 1), not the throat. Specimens should be obtained using polyester, rayon, nylon, or calcium alginate (not cotton) swabs and should be plated directly onto selective culture medium or placed in transport medium. Regan-Lowe agar or freshly prepared Bordet-Gengou medium is generally used for culture; half-strength Regan-Lowe should be used as the transport medium.

### Polymerase chain reaction for *B. pertussis* DNA

Polymerase Chain Reaction (PCR) is an important tool for timely diagnosis of pertussis and is increasingly available to clinicians. PCR is a molecular technique used to detect DNA sequences of the *Bordetella pertussis* bacterium, and unlike culture, does not require viable (live) bacteria present in the specimen.<sup>16, 17</sup>

Despite these advantages, PCR can give results that are falsely-negative or falsely-positive. PCR results can be optimized by avoiding some of the more common pitfalls leading to inaccurate results. Although early signs and symptoms of pertussis are often non-specific, only patients with signs and symptoms consistent with pertussis should be tested. Asymptomatic close contacts of confirmed cases should not be tested and testing of contacts should not be used for post-exposure prophylaxis decisions. Falsely-positive results may also occur as a result of specimen contamination, which can occur during specimen collection and testing. The


timing of PCR testing for pertussis can significantly affect its ability to accurately diagnose the disease. PCR has optimal sensitivity during the first 3 weeks of cough when bacterial DNA is still present in the nasopharynx. After the fourth week of cough, the amount of bacterial DNA rapidly diminishes which increases the risk of obtaining falsely-negative results.

Since its inclusion in the case definition in 1997, the proportion of cases confirmed by PCR has increased substantially, and many laboratories now use only PCR to confirm pertussis. However, as of March 2011, there are no standardized PCR assays for pertussis, and assay procedures, as well as sensitivity and specificity can vary greatly between laboratories. Thus, interpretation criteria for diagnosis vary. Interpretation of PCR results, especially those with high cycle threshold (Ct) values should be done in conjunction with an evaluation of signs and symptoms and available epidemiological information. For more information about interpretation of PCR Ct values, see Best Practices for Health Care Professionals on the use of Polymerase Chain Reaction (PCR) for Diagnosing Pertussis, which is located on the CDC Pertussis Website (<http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-pcr-bestpractices.html>).<sup>18</sup>

While PCR is increasingly used as the sole diagnostic test for pertussis, CDC recommends that PCR be used alongside culture, rather than as an alternative test. Even when a laboratory has validated its PCR method, culturing for *B. pertussis* should continue; this is especially important when an outbreak is suspected. State laboratories should retain the capability to culture pertussis.

Collection methods for PCR are similar to those for culture, and often the same sample can be used for both tests. **However, calcium alginate swabs cannot be used to collect nasopharyngeal specimens for PCR.**

**Figure 1: Proper technique for obtaining a nasopharyngeal specimen for isolation of *Bordetella pertussis***



### *Serologic testing*

Serologic testing can be a useful tool for diagnosis of pertussis. However, standardized tests are not available making the results of commercially available tests sometimes difficult to interpret. As of March 2011, positive serology results from a private laboratory are not confirmatory for the purpose of reporting. A single-point serologic assay has been validated at the Massachusetts state public health laboratory for persons aged 11 years or older and is used for clinical diagnosis and reporting in that state only.<sup>19</sup> A serologic test performed at CDC or at the Massachusetts state laboratory might be used to help investigate outbreaks. In states other than Massachusetts, cases meeting the clinical case definition that are serologically positive but not culture or PCR positive should be reported as probable cases.

### *Direct fluorescent antibody testing*

Direct fluorescent antibody (DFA) testing of nasopharyngeal secretions is sometimes used to screen for pertussis. While DFA testing can provide rapid results to providers treating ill infants, these results are not confirmatory because the tests are of variable specificity.<sup>13</sup> Since it is not a confirmatory test, DFA should be used alongside culture or PCR. Cases meeting the clinical case definition that are DFA positive but not culture or PCR positive should be reported as probable cases.

### *Pulsed-field gel electrophoresis*

Pulsed-field gel electrophoresis (PFGE), a type of DNA fingerprinting, can be performed on *B. pertussis* isolates to help track transmission (e.g., strains from the same household or small community), but it is not done for routine surveillance.<sup>20,21</sup>

Inquiries regarding PFGE molecular typing, erythromycin susceptibility testing, serologic testing and other *B. pertussis* laboratory questions should be directed to the CDC Epidemic Investigations Laboratory: Dr. M. Lucia Tondella, at 404-639-1239, or Ms. Pam Cassiday at 404-639-1231. When sending *B. pertussis* samples to CDC, please make appropriate arrangements with the laboratory before shipping samples to the address below:

Centers for Disease Control and Prevention  
1600 Clifton Road, NE  
DASH Unit 12  
Atlanta, GA 30333

Additional information on use of the laboratory for support of vaccine-preventable disease surveillance is available in Chapter 22, “Laboratory Support for Surveillance of Vaccine-Preventable Diseases.”

## **VIII. Reporting**

Each state and territory has regulations or laws governing the reporting of diseases and conditions of public health importance.<sup>22</sup> These regulations and laws list the diseases to be reported and describe those persons or institutions responsible for reporting, including healthcare providers, hospitals, laboratories, schools, daycare and childcare facilities, and other institutions. Persons reporting should contact the state health department for state-specific reporting requirements.

### *Reporting to CDC*

State health departments should report all probable and confirmed pertussis cases to NNDSS via the NETSS or NEDSS. When provisional information is reported to NNDSS, NETSS and NEDSS reports can be updated as additional information is collected. NETSS and NEDSS accept information about clinical symptoms, laboratory confirmation and vaccination history; this information is included in the Pertussis Surveillance Worksheet (Appendix 11) available for reference and use in case investigation.

### *Information to collect*

Case investigation should include collection of the epidemiologic information listed below. State health departments often supplement this list with additional information relevant to cases in their communities.

- Demographic
  - Name
  - State of residence
  - Date of birth
  - Age
  - Sex
  - Ethnicity
  - Race

- Reporting Source
  - County
  - Earliest date reported
- Clinical
  - Hospitalization and duration of stay
  - Cough, date of cough onset and duration
  - Symptoms: paroxysms, whoop, posttussive vomiting, apnea
  - Complications: pneumonia (x-ray results), seizures, encephalopathy
  - Outcome (patient survived or died) and date of death
- Treatment
  - Antibiotics used
  - Date started and duration of therapy
- Laboratory
  - Culture
  - PCR
  - Serology for antibody to pertussis antigens
- Vaccination with pertussis-containing vaccine
  - Dates of vaccination
  - Type (formulation) of vaccines and manufacturers' names
  - Doses of pertussis-containing vaccine prior to illness onset
  - If not vaccinated with at least three doses of DTaP or DTP, reason
- Epidemiologic
  - Date case investigation initiated
  - Epidemiologic linkage to a laboratory-confirmed case
  - Association with an outbreak
  - Transmission setting
  - Setting outside household of further documented spread

### *Comments on reporting*

The limitations of laboratory diagnostics make the clinical case definition essential to pertussis surveillance. It is important to determine duration of cough—specifically whether it lasts 14 days or longer—in order to determine if a person's illness meets the definition of a clinical case. If the first interview is conducted within 14 days of cough onset and cough is still present at the time of interview, it is important to follow up at 14 days or later after onset.

Accurate assessment of pertussis symptoms can be challenging. The following symptom definitions and variable explanations are appropriate for pertussis case investigations.

**Paroxysmal or spasmodic cough.** Sudden uncontrollable “fits” or spells of coughing where one cough follows the next without a break for breath.

**Whoop.** High-pitched noise heard when breathing in after a coughing spasm.

**Apnea.** Transient cessation of respiration which might occur spontaneously or after a coughing spasm. Apnea is generally associated with cyanosis or syncope (passing out) and might be accompanied by slowing of the heartbeat (bradycardia). Apnea is a common pertussis symptom in infants and might be the only presenting sign of pertussis in young infants with no cough; apnea is rarely associated with pertussis in older children and adults.

**Cyanosis.** Paleness or blueness of the skin, most noticeable on the lips and tongue, occurring after coughing paroxysms and apnea.

**Posttussive vomiting.** Vomiting following paroxysms of cough.

**Cold-like symptoms.** Coryza (runny nose) and/or conjunctival infection (redness of the eyes).

**Positive chest x-ray for pneumonia.** Evidence of acute pneumonia on chest x-ray.

**Acute encephalopathy.** Acute illness of the brain manifested by a decreased level of consciousness (excluding transient drowsiness after a seizure) occurring with or without seizures. Patients are almost always hospitalized and most undergo extensive diagnostic evaluations.

## IX. Vaccination

Currently, the pertussis vaccines available in the United States are acellular pertussis antigens in combination with diphtheria and tetanus toxoids (DTaP, DTaP- combination vaccines, and Tdap).

The Advisory Committee on Immunization Practices (ACIP) recommends a four-dose primary series of DTaP, administered at 2, 4, 6 and 15–18 months of age, followed by a fifth booster dose given at 4–6 years.<sup>22</sup> In 2005 and 2006, the ACIP recommended the replacement of a single Td booster with a dose of Tdap for adolescents (ages 11–18) and adults (ages 19–64),<sup>6, 23</sup> who have not previously received Tdap.

On October 27, 2010, ACIP expanded Tdap recommendations to include both under-vaccinated children and senior adults. The new recommendations state that children aged 7-10 years who are not up-to-date with their childhood pertussis vaccinations should receive a single dose of Tdap. Additionally, Tdap is recommended for adults aged 65 years and older who anticipate close contact with an infant and who have not previously received the vaccine. ACIP further recommended that Tdap be administered regardless of time since last tetanus and diphtheria-containing booster.<sup>24</sup> On February 23, 2011, ACIP recommended that all healthcare personnel who have not yet received a dose of Tdap, regardless of age, should be vaccinated.

**Table 1** lists vaccines likely to appear in case-patients' vaccination histories. Immunization Information Systems, provider records, and parents are the best sources of this information.

**Table 1. Pertussis-containing vaccines**

Pertussis-Containing Vaccines for Children	Brand	Licensed Date and Used For
DTaP	INFANRIX® DAPTACEL® Tripedia®	First licensed in 1991; used for all childhood doses
DTaP+Hib	TriHiBit®	Used for the fourth dose only
DTap+IPV+HepB	PEDIARIX®	Used for the first three doses
DTap+IPV+Hib	PENTACEL™	Approved in 2008; used for primary four-dose series
DTap+IPV	KINRIX™	Approved in 2008; used for booster dose at 4–6 years
Pertussis-Containing Vaccines for Adolescents and Adults	Brand	Licensed Date
Tdap	ADACEL® BOOSTRIX®	First available in 2005
Other Vaccines	Brand	Licensed Date
Pertussis Only		Not available in the U.S.
DT/Td	DECAVAC™ TENIVAC™	Do not contain pertussis; DT used for primary series when pertussis vaccination is contraindicated; Td used in persons aged ≥7 years

## X. Enhancing Surveillance

A number of surveillance activities can improve detection and reporting of cases as well as the completeness and accuracy of the information reported. In addition to those outlined below, Chapter 19, "Enhancing Surveillance," lists activities that might be applicable to pertussis surveillance.

### *Assuring appropriate diagnostic testing for pertussis is being performed regularly*

Unlike many other vaccine-preventable diseases of childhood, pertussis remains endemic in the United States. Cases are expected to occur in all communities; a period of several years in which no cases are reported from a jurisdiction likely reflects failures to diagnose and/or report disease rather than an absence of disease. The level of diagnostic testing being undertaken can be evaluated by reviewing the number of pertussis diagnostic tests (e.g., cultures or PCR results) submitted by a jurisdiction.

### *Monitoring surveillance indicators*

Regular monitoring of surveillance indicators might identify specific areas of the surveillance and reporting system that need improvement. Some suggested surveillance indicators to monitor include:

- The proportion of probable cases that did not meet the clinical case definition because the cough duration was less than 14 days and the patient was coughing at follow-up. These are cases for which later follow-up calls can improve case status classification.
- The proportion of probable and confirmed cases with complete information on vaccination history (dates, vaccine types and manufacturers). Now that pertussis vaccination is available for adolescents and adults, many states will for the first time be collecting vaccination histories for adolescents and adults. Some electronic reporting systems will require coding changes to allow this information to be entered.
- Median interval between onset of cough and notification of state or local public health authorities in probable and confirmed cases.

## **XI. Case Investigation**

Case investigations generally include reviews of laboratory, hospital, clinic records, and immunization registries, which are the best sources for information about diagnoses and immunization histories. Investigations also include interviews of case-patients, which are necessary to identify sources of infections and contacts at risk. Investigations can include treatment of case-patients and chemoprophylaxis and or vaccination of contacts.

### *Treatment and chemoprophylaxis*

Antimicrobial treatment does not generally lessen the severity of disease unless it is begun in the catarrhal phase, prior to paroxysmal coughing.<sup>25</sup> Treatment reduces transmission and is essential for disease control. The spread of pertussis can be limited by decreasing the infectivity of the patient and by protecting close contacts.<sup>26</sup> Persons with pertussis are infectious from the beginning of the catarrhal stage through the third week after the onset of paroxysms or until 5 days after the start of effective antimicrobial treatment. The recommended antimicrobial agents and doses are the same for treatment and chemoprophylaxis.<sup>27</sup>

Three macrolides are recommended by CDC for treatment of pertussis. Azithromycin is most popular because it is given in a short, simple regimen of one dose each day for 5 days. It is the preferred antimicrobial for use in infants younger than 1 month of age. Similarly, the regimen of two doses a day for 7 days makes clarithromycin another well-accepted choice. Erythromycin, which is given as four doses each day for 14 days, continues to be used, but adherence to the regimen and completion of the course are generally lower than for the other macrolides, and adverse effects (gastrointestinal distress, pyloric stenosis, etc.) occur more frequently. Resistance of *B. pertussis* to macrolides is rare, and antimicrobial susceptibility testing is not routinely recommended. Testing is appropriate in some circumstances and is recommended when treatment failure is suspected. Refer to Section VII, “Laboratory Testing” for information on how to contact the CDC Pertussis Laboratory to discuss susceptibility testing. If resistance to macrolides is suspected or if their use is contraindicated, CDC recommends treatment with trimethoprim–sulfamethoxazole (TMP-SMZ) in a regimen of two doses a day for 14 days. TMP-SMZ should not be used to treat infants younger than 2 months of age.<sup>27</sup>

CDC recommends administration of chemoprophylaxis to all close contacts and all household members of a pertussis case-patient, regardless of age and vaccination status; this might prevent

or minimize transmission. A close contact is anyone who had face-to-face contact or shared a confined space for a prolonged period of time with an infected person or had direct contact with respiratory secretions from a symptomatic person. Contact with respiratory secretions can occur in many ways, including through an explosive cough or sneeze in the face, sharing food or eating utensils, mouth-to-mouth resuscitation, and conducting a medical exam which includes nose and throat examination.<sup>27</sup>

Limited available data suggests *Bordetella parapertussis* is less susceptible to antibiotics than pertussis; erythromycin, azithromycin, clarithromycin, TMP-SMZ, and ciprofloxacin may have activity against *B. parapertussis*.<sup>27-35</sup> No clinical studies have evaluated the effectiveness of these antibiotics for treatment or chemoprophylaxis; however, prophylaxis of infant contacts of persons with *B. parapertussis* infection should be considered, and infants with *B. parapertussis* should be treated.

### Vaccination

Close contacts younger than 7 years of age who have not received four doses of a pertussis vaccine should complete the series using the minimum recommended intervals between doses (minimum age for first dose is 6 weeks; minimum intervals from dose 1 to dose 2, and from dose 2 to dose 3 are 4 weeks; minimum interval from dose 3 to dose 4 is 6 months). Vaccination with a fifth dose of DTaP is recommended for close contacts aged 4–6 years who have only received four doses. Close contacts can be vaccinated with Tdap in accordance with ACIP recommendations. Vaccination is not a substitute for chemoprophylaxis and might not prevent illness in a person who has already been infected with *B. pertussis*.<sup>23,24,36</sup>

## XII. Outbreak Control

Pertussis outbreaks can be difficult to identify and manage. Other respiratory pathogens often cause clinical symptoms similar to pertussis, and co-circulation with other pathogens does occur. To respond appropriately (e.g., provide appropriate prophylaxis), it is important to confirm that *B. pertussis* is circulating in the outbreak setting and to determine whether other pathogens are contributing to the outbreak. PCR tests vary in specificity, so obtaining culture confirmation of pertussis for at least one suspected case is recommended any time there is suspicion of a pertussis outbreak.

If cases are occurring among young infants, consideration can be given to vaccinating infants at an accelerated schedule. The first dose of DTaP can be given as early as 6 weeks of age, with a minimum interval of 4 weeks between each of the first three doses. Adults in close contact with infants should be vaccinated with Tdap, particularly during an outbreak. The ACIP recommends vaccination of postpartum mothers who have not previously received Tdap.<sup>6</sup>

Institutional outbreaks of pertussis are common. Outbreaks at elementary, middle and high schools can occur as protection from childhood vaccines wanes.<sup>23</sup> In school outbreaks, prophylaxis is recommended for close classroom and sports team contacts.

Pertussis outbreaks in hospitals and other clinical settings can put infants and other patients at risk. Health-care facilities should maximize efforts to prevent transmission of *B. pertussis*. Respiratory precautions should be taken to prevent unprotected exposure to pertussis. Data on the need for postexposure antimicrobial prophylaxis in Tdap-vaccinated healthcare personnel (HCP) are inconclusive. Some vaccinated HCP are still at risk for *B. pertussis*. Tdap may not preclude the need for postexposure antimicrobial prophylaxis. Postexposure antimicrobial prophylaxis is recommended for all HCP who have unprotected exposure to pertussis and are likely to expose a patient at risk for severe pertussis (e.g., hospitalized neonates and pregnant women). Other HCP should either receive postexposure antimicrobial prophylaxis or be monitored daily for 21 days after pertussis exposure and treated at the onset of signs and symptoms of pertussis.

The efficacy of Tdap vaccination in controlling school or institutional outbreaks has not been evaluated; those who have not previously received Tdap can be vaccinated in accordance with the ACIP guidelines for Tdap use in outbreaks and settings of increased risk.<sup>23,37</sup>

## References

1. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. *Pediatr Infect Dis J* 2003;22:628–34.
2. Davis SF, Strebel PM, Cochi SL, Zell ER, Hadler SC. Pertussis surveillance—United States, 1989–1991. *MMWR* 1992;41(No. SS-8):11–19.
3. CDC. Pertussis—United States, 2001–2003. *MMWR* 2005;54(50):1283–6.
4. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. *Clin Infect Dis* 1999; 28:1230–7.
5. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? *Pediatr Infect Dis J* 2004; 23:985–9.
6. CDC. Prevention of diphtheria, tetanus, and pertussis among pregnant women: provisional recommendations for use of Tdap in pregnant women. Atlanta, GA. 2006. Available at <http://www.cdc.gov/vaccines/recs/provisional/>
7. CDC. ACIP votes to recommend use of combined tetanus, diphtheria and pertussis (Tdap) vaccine for adults. 2006. Atlanta, GA: CDC, 2006.
8. U.S. Department of Health and Human Services. *Healthy People 2010*. 2nd. ed. With understanding and improving health and objectives for improving health (2 vols.). Washington DC: US Department of Health and Human Services, 2000.
9. Council of State and Territorial Epidemiologists. CSTE Position Statement 1997-ID-9: Public health surveillance, control and prevention of pertussis. CSTE, 1997. Available at <http://www.cste.org/ps/1997/1997-id-09.htm>
10. Patriarca PA, Biellik RJ, Sanden G, Burstyn DG, Mitchell PD, Silverman PR, et al. Sensitivity and specificity of clinical case definitions for pertussis. *Am J Public Health* 1988; 78:833–6.
11. Bejuk D, Begovac J, Bace A, Kuzmanovic-Sterk N, Aleraj B. Culture of *Bordetella pertussis* from three upper respiratory tract specimens. *Pediatr Infect Dis J* 1995;14:64–5.
12. Hallander HO, Reizenstein E, Renemar B, Rasmuson G, Mardin L, Olin P. Comparison of nasopharyngeal aspirates with swabs for culture of *Bordetella pertussis*. *J Clin Microbiol* 1993;31:50–2.
13. Halperin SA, Bortolussi R, Wort AJ. Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. *J Clin Microbiol* 1989; 7:752–7.
14. Hoppe JE, Weiss A. Recovery of *Bordetella pertussis* from four kinds of swabs. *Eur J Clin Microbiol* 1987;6:203–5.
15. Loeffelholz M. *Bordetella*. In: Murray P, Barron E, Jorgenses J, Pfaller M, Tenover FC, Tenover FC, eds. *Manual of clinical microbiology*. Washington D.C.: American Society for Microbiology, 2003.
16. Koidl C, Bozic M, Burmeister A, Hess M, Marth E, Kessler HH. Detection and differentiation of *Bordetella* spp. by real-time PCR. *J Clin Microbiol* 2007;45:347–50.
17. Qin X, Galanakis E, Martin ET, Englund JA. Multi-target polymerase chain reaction for diagnosis of pertussis and its clinical implications. *J Clin Microbiol* 2007;45:506–11.
18. CDC. Best practices for health care professionals on the use of polymerase chain reaction (PCR) for diagnosing pertussis. 2011. Atlanta, GA: CDC, 2011. Available at <http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-pcr-bestpractices.html>
19. Marchant CD, Loughlin AM, Lett SM, Todd CW, Wetterlow LH, Bicchieri R, et al. Pertussis in Massachusetts, 1981–1991: incidence, serologic diagnosis, and vaccine effectiveness. *J Infect Dis* 1994;169:1297–1305.
20. Bisgard KM, Christie CD, Reising SF, Sanden GM, Cassidy PK, Gomersall C, et al. Molecular epidemiology of *Bordetella pertussis* by pulsed-field gel electrophoresis profile: Cincinnati, 1989–1996. *J Infect Dis* 2001;183:1360–7.

21. de Moissac YR, Ronald SL, Pepler MS. Use of pulsed-field gel electrophoresis for epidemiological study of *Bordetella pertussis* in a whooping cough outbreak. *J Clin Microbiol* 1994;32:398–402.
22. CDC. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46(No. RR-7):1–25.
23. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;559(No. RR-3):1–34.
24. CDC. Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine from the Advisory Committee on Immunization Practices, 2010. *MMWR* 2011;60(01):13-15.
25. Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin S, Orenstein WA, eds. *Vaccines*. Philadelphia, PA.: Saunders Co., 2004: 471–528.
26. American Academy of Pediatrics. Pertussis. In: Pickering LK, ed. *Red Book: 2003 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics, 2003: 472–86.
27. CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. *MMWR* 2005;54(No. RR-14):1–16.
28. Mastrantonio P, Stefanelli P, Giuliano M, Herrera Rojas Y, Ciofi degli Atti M, Anemona A, Tozzi AE. *Bordetella parapertussis* infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. *J Clin Microbiol* 1998;36:999-1002.
29. Hoppe JE, Tschirner T. Comparison of media for agar dilution susceptibility testing of *Bordetella pertussis* and *Bordetella parapertussis*. *Eur J Clin Microbiol Infect Dis* 1995;14:775-9.
30. Hoppe JE, Bryskier A. In vitro susceptibilities of *Bordetella pertussis* and *Bordetella parapertussis* to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). *Antimicrob Agents Chemother* 1998;42:965-6.
31. Hoppe JE, Tschirner T. Comparison of Etest and agar dilution for testing the activity of three macrolides against *Bordetella parapertussis*. *Diagn Microbiol Infect Dis* 1997;28:49-51.
32. Hoppe JE, Rahimi-Galougahi E, Seibert G. In vitro susceptibilities of *Bordetella pertussis* and *Bordetella parapertussis* to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem. *Antimicrob Agents Chemother* 1996;40:807-8.
33. Hoppe JE, Simon CG. In vitro susceptibilities of *Bordetella pertussis* and *Bordetella parapertussis* to seven fluoroquinolones. *Antimicrob Agents Chemother* 1990;34:2287-8.
34. Hoppe JE, Eichhorn A. Activity of new macrolides against *Bordetella pertussis* and *Bordetella parapertussis*. *Eur J Clin Microbiol Infect Dis* 1989;8:653-4.
35. Watanabe M, Haraguchi Y. In vitro susceptibility of *Bordetella parapertussis* to various antimicrobial agents. *Antimicrob Agents Chemother* 1989;33:968-9.
36. Kurzynski TA, Boehm DM, Rott-Petri JA, Schell RF, Allison PE. Antimicrobial susceptibilities of *Bordetella* species isolated in a Multicenter Pertussis Surveillance Project. *Antimicrob Agents Chemother* 1988;32:137-40.
37. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. *MMWR* 2006;55(No. RR-17):1–37.